Pages that link to "Q35095218"
Jump to navigation
Jump to search
The following pages link to Omalizumab, an anti-immunoglobulin E antibody: state of the art. (Q35095218):
Displaying 18 items.
- Shifting Focus in the Therapeutics of Immunobullous Disease (Q33737974) (← links)
- Omalizumab in children (Q34604574) (← links)
- Evolution of anti-IgE treatment (Q36870053) (← links)
- IgE-Related Chronic Diseases and Anti-IgE-Based Treatments (Q37554168) (← links)
- Burden and distinctive character of allergic bronchopulmonary aspergillosis in India (Q38221676) (← links)
- Focusing the mechanism of action to dissect the different treatments of respiratory allergy (Q38542919) (← links)
- Omalizumab therapy for children and adolescents with severe allergic asthma. (Q38574776) (← links)
- Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. (Q38754492) (← links)
- Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody (Q38811111) (← links)
- Comparable actions of omalizumab on mast cells and basophils (Q38824255) (← links)
- Are allergic fungal rhinosinusitis and allergic bronchopulmonary aspergillosis lifelong conditions? (Q38948097) (← links)
- Effect of anti-IgE in occupational asthma caused by exposure to low molecular weight agents. (Q47218290) (← links)
- New approaches for identifying and testing potential new anti-asthma agents. (Q47873103) (← links)
- Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy. (Q48256010) (← links)
- Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. (Q52976551) (← links)
- Eosinophils from Physiology to Disease: A Comprehensive Review. (Q55311740) (← links)
- Successful treatment of idiopathic mast cell activation syndrome with low-dose Omalizumab (Q90427825) (← links)
- The effect of omalizumab treatment on severe allergic asthma and allergic comorbidities: real-life experience from the Czech Anti-IgE Registry (Q93081919) (← links)